1.495USD-0.66%Mkt Cap: 73.43M USDP/E: —Last update: 2026-06-01
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical t…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap73.43M USD
Enterprise Value-29.80M USD
Revenue (TTM)—
Gross Profit-26.59M USD
Net Income (TTM)-90.97M USD
Revenue/Share—
Last Price1.495 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG1.62
EV/EBITDA0.50
EV/Revenue—
P/S—
P/B1.00
EPS (TTM)-1.61
EPS (Forward)—
52W Range
1.1609% of range4.980
52W High4.980 USD
52W Low1.160 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-122.27%
ROA-76.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.25M USD
CapEx (TTM)581.00K USD
FCF Margin—
FCF Yield27.53%
Net Debt-95.50M USD
Net Debt/EBITDA1.61
Balance Sheet
Debt/Equity—
Current Ratio2.23
Quick Ratio2.18
Book Value/Sh1.540 USD
Cash/Share1.977 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateDec 13, 2012
Pay Date—
Splits
Last Split1:7
Split DateMay 10, 2017
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)6.500 USD
Target Range5.000 USD – 8.000 USD
# Analysts2
Ownership
Shares Out.48.31M
Float45.05M
Insiders11.02%
Institutions29.03%
Short Interest
Short Ratio19.0d
Short % Float14.64%
Short % Out.14.34%
Shares Short6.93M
Short (prev mo.)7.32M
Technical
SMA 501.553 (-3.7%)
SMA 2002.367 (-36.8%)
Beta-0.76
S&P 52W Chg27.94%
Avg Vol (30d)394.23K
Avg Vol (10d)382.22K
Technical Indicators
RSI (14)55.5
MACD-0.0297
MACD Signal-0.0809
MACD Hist.+0.0513
BB Upper1.584 USD
BB Middle1.338 USD
BB Lower1.092 USD
BB Width36.81%
ATR (14)0.1013 USD
Vol Ratio (20d)0.82x